"Seasonality-driven molecules and molecular combinations, especially anti-infectives, have shown a relatively stronger volume-driven growth," the firm stated in its report
The decrease in the group's consolidated Ebitda margin is being attributed to the negative Ebitda reported by Cenexi, its recent acquisition
Analysts say pharmaceutical company's stock fully priced in
Over 400 drug manufacturing units, including MSMEs, inspected after high frequency of NQS reports
Contract manufacturer Akums Drugs plans expansion; targets higher margins
Revenues in the USA market, however, were down by 12 per cent at Rs 259 crore, falling from Rs 293 crore reported in Q1 FY24
Firms term DCGI move 'positive' as it aims at ensuring patient safety
Dr. Reddy's will market Vonoprazan tablets under its own brand Vono, and it will be available in two strengths, 10 mg and 20 mg
Cipla's share price declined by 0.56 per cent, ending the day's trade at Rs 1,507.50 apiece on the BSE
Mukesh Aghi talks about the recent Lok Sabha elections, expectations from the coming Budget, changes in India's regulatory environment.
The specific price and date of the offer for sale will likely be announced in the future
This will be the company's largest GCC in the world. This is a monumental addition by the company, joining other global giants like Hitachi Energy in establishing their biggest GCCs in Chennai
GSK Pharma's recent good showing is on expectations that launches in the specialty segment, increasing investments in promotions and branding
Hailing from Okari, a remote village in Jehanabad district of Bihar, Singh and his brother, Samprada, moved to Mumbai in 1973 to start Alkem Laboratories with a seed capital of Rs 5 lakh
The share of chronic has been steadily rising in the Rs 2 lakh crore domestic pharma market- from 36.4 percent in January 2022 to 38.1 percent in January 2024
Companies must commit that they comply with a code against unethical marketing of drugs
Marksans Pharma's net profit fell 4.5 per cent on a year-on-year (Y-o-Y) basis to Rs 78.3 crore in the March quarter of FY24, from Rs 82 crore in the March quarter of FY23
Strategic collaborations played a crucial role in AstraZeneca's achievements, particularly in enhancing diagnostic capabilities and treatment outcomes
The approval for the generic version of Lanreotide Acetate is in line with Cipla's growth strategy in the complex product segment and will strengthen Cipla's position in the US market.
Manufacturer AstraZeneca Pharma India says its study shows drug may have detrimental effect